Shinmi et al. evaluated a novel anti-CEA antibody, 15-1-32, that showed strong binding of CEA membrane on cancer cells rather than existing anti-CEA antibodies, also increasing the efficacy of its therapeutic through monomethyl auristatin E (vcMMAE) conjugation. Here, CEACAM5 is linked to cancer.